Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
About XOMA Royalty Corporation
XOMA Royalty Corporation (NASDAQ: XOMA) is a biotechnology royalty aggregator that plays a pivotal role in advancing the development of innovative therapeutic solutions. The company specializes in acquiring the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. By doing so, XOMA provides non-dilutive, non-recourse funding to biotech firms, enabling them to accelerate the development of their internal drug pipelines or meet other corporate objectives.
Business Model and Operations
XOMA's business model is centered around acquiring royalty and milestone rights from therapeutic assets across all stages of development. These assets span a wide range of therapeutic areas, including oncology, rare diseases, women's health, and cardio-respiratory conditions. By focusing on royalty aggregation rather than direct drug development, XOMA minimizes operational risks while maximizing potential financial returns. The company’s portfolio includes rights to commercial products such as VABYSMO®, OJEMDA™, MIPLYFFA™, and DSUVIA®, as well as a pipeline of investigational compounds with significant market potential.
Industry Significance
Operating at the intersection of biotechnology and finance, XOMA serves as a critical enabler for biotech innovation. Its royalty aggregation model provides biotech companies with the financial flexibility to advance groundbreaking therapies without the burden of equity dilution or traditional debt. This unique approach not only supports the development of life-saving treatments but also allows XOMA to build a diversified portfolio of assets that generate sustainable cash flows over time.
Portfolio and Market Position
XOMA boasts an extensive and growing portfolio of over 70 assets, including both commercial and investigational therapies. The company's portfolio strategy emphasizes diversification across therapeutic areas and stages of development, thereby mitigating risks associated with the inherently unpredictable nature of drug development. Recent acquisitions, such as economic interests in seralutinib for pulmonary arterial hypertension and XACIATO™ for bacterial vaginosis, highlight XOMA's commitment to expanding its asset base while addressing unmet medical needs.
Competitive Differentiation
XOMA differentiates itself through its expertise in asset valuation, strategic capital deployment, and risk diversification. Unlike traditional biotech firms that focus on drug development, XOMA’s royalty aggregation model allows it to benefit from the success of multiple therapeutic candidates without bearing the direct costs and risks of R&D. This positions XOMA as a trusted financial partner for biotech companies and a unique investment opportunity within the biotech sector.
Challenges and Risk Management
While XOMA's business model reduces operational risks, it is not without challenges. The company’s revenue streams depend on the successful development, regulatory approval, and market adoption of its partnered assets. To mitigate these risks, XOMA employs a disciplined approach to asset selection, focusing on therapies with strong clinical and commercial potential. Its diversified portfolio further helps to balance the inherent uncertainties of the biotech industry.
Conclusion
In summary, XOMA Royalty Corporation represents a unique and innovative approach to supporting biotech innovation. By acquiring royalty and milestone rights, the company enables the development of life-saving therapies while building a diversified and sustainable revenue model. With its extensive portfolio, strategic focus, and financial expertise, XOMA continues to play a crucial role in advancing human health and shaping the future of biotechnology.
XOMA Corporation has announced a public offering of 1,400,000 depositary shares at $25.00 each, raising $35.0 million in gross proceeds. Each share represents a 1/1000th interest in the company’s 8.375% Series B Cumulative Perpetual Preferred Stock. The offering, with a 30-day underwriter option for 200,000 additional shares, is set to close around April 9, 2021. Proceeds will fund a segregated dividend account and general corporate purposes, including future acquisitions related to drug development. Shares will trade under the symbol XOMAO.
XOMA Corporation has initiated an underwritten public offering of depositary shares, each representing a 1/1000th fractional interest in its Series B Cumulative Perpetual Preferred Stock, priced at a liquidation preference of $25.00 per depositary share. The offering, led by several financial institutions, will use net proceeds primarily for funding acquisitions related to drug development programs. XOMA's offering is registered under an effective Form S-3 with the SEC, and additional shares may be available for purchase by underwriters.
Viracta Therapeutics (Nasdaq: VIRX) and XOMA Corporation (Nasdaq: XOMA) announced the acquisition of milestone and royalty rights for two clinical-stage drug candidates through a $13.5 million upfront payment. XOMA may pay up to $20 million in milestone payments. The candidates include DAY101, in a Phase 2 trial for pediatric glioma, and vosaroxin, aimed at treating acute myeloid leukemia. This deal is expected to provide Viracta with non-dilutive capital to support upcoming trials for Epstein-Barr virus-related cancers.
XOMA Corporation (Nasdaq: XOMA) announced a cash dividend of $0.71875 per share for its Series A Cumulative Perpetual Preferred Stock (XOMAP). The dividend will be paid on or about April 15, 2021, to shareholders on record as of the close of business on April 2, 2021. This reflects the company’s ongoing commitment to returning value to its shareholders.
XOMA has developed a diverse portfolio licensed to other biotech firms, focusing on milestone and royalty opportunities within drug development.
XOMA Corporation reported a recognized revenue of $29.4 million for 2020, a significant increase from $18.4 million in 2019. The company achieved a milestone earning of $25 million following Novartis' Phase 2 trial initiation of NIS793 for metastatic pancreatic cancer. XOMA also completed a $24.6 million Series A Preferred Stock offering, paying an 8.625% dividend. As of December 31, 2020, XOMA held $84.2 million in cash, marking a solid financial position to support future operations and projects.
On February 23, 2021, XOMA Corporation announced that CEO Jim Neal will present at two upcoming investor conferences. He will participate in a panel at the Cowen 41st Annual Virtual Health Care Conference on March 2, 2021, discussing clinical development. Additionally, XOMA will present at the H.C. Wainwright Global Life Sciences Conference, with on-demand access starting March 9, 2021. XOMA specializes in a portfolio of partnered programs and antibody therapeutics, aiming to generate milestone and royalty revenues for shareholders.
XOMA Corporation (NASDAQ: XOMA) announced that CEO Jim Neal will present at two upcoming investor conferences. The H.C. Wainwright Virtual BioConnect 2021 Conference, running from January 11-14, 2021, will feature XOMA’s presentation available on-demand starting January 11 at 6:00 AM ET. Additionally, XOMA will present at the Biotech Showcase Digital Conference from January 11-15, 2021, accessible to registered participants. Replays of these presentations will be archived for 90 days on XOMA's investor relations website.
XOMA Corporation has successfully completed an underwritten public offering of 984,000 shares of its 8.625% Series A Cumulative Perpetual Preferred Stock at $25.00 per share, raising approximately $23.4 million in net proceeds. The funds will support a segregated dividend account and general corporate purposes, including future acquisitions related to drug development programs. The Preferred Stock trades under the symbol ‘XOMAP’ on Nasdaq. XOMA continues to expand its portfolio of partner-funded drug development programs across various therapeutic areas.
XOMA Corporation announced the pricing of its public offering of 880,000 shares of 8.625% Series A Cumulative Perpetual Preferred Stock at $25.00 per share, raising gross proceeds of $22.0 million. A 30-day option allows underwriters to purchase an additional 104,000 shares. The offering is set to close on December 15, 2020, subject to conditions. Proceeds will fund a segregated dividend account and support general corporate purposes, including acquiring milestone and royalty rights for drug development programs. The shares will trade under the symbol 'XOMAP' on NASDAQ if approved.
XOMA Corporation announced a public offering of its Series A Cumulative Perpetual Preferred Stock at a liquidation preference of $25.00 per share. The offering includes a 30-day option for underwriters to purchase additional shares. Proceeds will fund a segregated dividend account and support general corporate purposes, including acquisitions of milestone and royalty rights for drug development. The offering is conducted under an effective shelf registration statement. Joint book-runners for the offering include B. Riley Securities and others.
FAQ
What is the current stock price of XOMA Royalty Corporation (XOMA)?
What is the market cap of XOMA Royalty Corporation (XOMA)?
What does XOMA Royalty Corporation do?
How does XOMA generate revenue?
What is XOMA's business model?
What therapeutic areas does XOMA focus on?
What makes XOMA unique in the biotech industry?
What are some commercial assets in XOMA's portfolio?
How does XOMA mitigate risks in its business model?
Who benefits from XOMA's royalty aggregation model?
What role does XOMA play in the biotech industry?
What is XOMA's approach to portfolio management?
